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Background: Four novel direct oral anticoagulants (DOACs) named dabigatran, rivaroxaban, edoxaban and apixa-
ban have been recently introduced to overcome some of the drawbacks of existing anticoagulants. They have less 
interactions and do not require routine monitoring. However, there is not enough scientific data about the protocol 
to apply in these patients on DOACs undergoing dental treatment. Thus is necessary to evaluate the potential blee-
ding risk of these drugs, the possibility of thromboembolic events occurring if they are withdrawn or the need to 
change to heparin previously. 
Material and Methods: A comprehensive search of the PubMed, Scopus and ISI Web of Science databases was con-
ducted to identify studies that evaluated the relationship between direct oral anticoagulants and dental procedures. 
The quality of the reported information was assessed following the PRISMA statement.
Results: Eleven studies that met the inclusion criteria were included in the review: 2 randomized clinical trials, 3 
prospective studies, 3 retrospective studies, 2 case series and 1 case report. 
Conclusions: DOACs are safe drugs in terms of bleeding. The possible postoperative bleeding complications are 
manageable with conventional haemostasis measurements. The bridging approach with heparin does not seem to 
be recommended. Consensus among the professionals involved in the management of the patient is fundamental in 
invasive dental treatments and in complex patients.
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Introduction
Nowadays, anticoagulation therapy is required by a lot 
of patients to prevent, treat or reduce the risk of throm-
boembolism in atrial fibrillation, treatment of venous 
thromboembolism, cerebro-vascular accidents, ischae-
mic heart disease, myocardial infarction, pulmonary 
embolism and in prevention of thromboembolism after 
hip and knee replacement or stent placement, bypass 
surgery and prosthetic heart valve placement (1-3). 
Historically, vitamin K antagonists such as warfarin 
and acenocumarol, have been the oral anticoagulants of 
choice (4). However they have some disadvantages such 
as low therapeutic index, delayed onset of action, many 
drug and food interactions and difficult pharmacological 
management since they require a regular monitoring and 
adjustment (5,6).
In the recent years, Direct Oral Anticoagulants (DOACs) 
have been introduced in order to eliminate some of the-
se disadvantages. The first four DOACs are: dabigatran, 
rivaroxaban, apixaban and edoxaban (Table 1). This 
novel agents target specific proteins or proteases of the 
coagulation cascade such as thrombin or activated factor 
Xa (2,5). They have an immediate onset of action, more 
predictable pharmacokinetics, less drug interactions than 
warfarin and a short half-life (7). The most important di-
sadvantage is that there is no specific agent to reverse the 
anticoagulant effect of DOACs.
-Dabigatran
Dabigatran etexilate is a low molecular weight prodrug 
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Table 1: Pharmacological properties of DOACs.
bound thrombin (5). It has short half-life (12-17 hours) 
and rapid onset of action, its peak in plasma takes place 
2-3 hours after administration, which is one or twice per 
day (4,5,8,9).  80% is excreted renally and the remaining 
20% is cleared by hepatic metabolism. So in patients 
with reduced renal function, the dose needs to be adjus-
ted depending on the creatinine clearance.
One of the major advantages is that does not require 
routine monitoring of anticoagulant effect, due to its pre-
dictable pharmacokinetics and dose response. However, 
in some situations it may be necessary an assessment 
of anticoagulation. Prothrombin time (PT) expressed as 
the INR, which most dentists are familiar with, is not a 
sensitive test and is not normally affected by dabigatran. 
An accurate test that can be useful is thrombin clotting 
time (TT) (3-5). 
The most frequent adverse effects experienced by the 
patients (>15% of patients) are gastritis type symptoms 
such as dyspepsia, abdominal pain and epigastric dis-
comfort. Minor bleeding events were reported by 8-33% 
of the patients and major bleeding events by ≤6% of the 
patients (3,10,11). 
The major disadvantage is that there is no specific anti-
dote or reversal agent for an emergency situation. Dabi-
gatran can be partially reversed with haemodialysis (5). 
-Rivaroxaban
Rivaroxaban is an orally administered, selective, rever-
sible, direct inhibitor of activated factor X (factor Xa) 
anticoagulant (3,4). It inhibits directly factor Xa, there-
fore it interrupts the extrinsic and intrinsic coagulation 
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pathways. The plasma concentration peak of rivaroxa-
ban is 2-4 hours after administration and its half-life in 
plasma is 7-13 hours. It is excreted basically in the urine 
(67-85%). It may be necessary some dose adjustments 
in patients with severe renal impairment if the plasma 
levels increase (8,12).
Like dabigatran, it is not required a routine monitoring. 
However, in an emergency situation an anti-factor Xa 
assay can be useful (3,4).
The adverse effects are experienced by 1-10% of the pa-
tients. Major bleeding has been reported in 1-2% of the 
patients, and minor bleeding in 4-7% (4,13). 
The most important disadvantage is that there is no spe-
cific agent to reverse the anticoagulant effect of riva-
roxaban. For a minor haemorrhage, due to its short half-
life, discontinuation of the treatment should be enough. 
However, in major haemorrhages it may be necessary a 
blood transfusion (4,8).
-Apixaban
Apixaban is a direct inhibitor of activated factor X (it 
blocks the active site of Xa), like rivaroxaban conse-
quently it has very similar properties (12). 
Apixaban has a rapid onset of action: the plasma con-
centration peak is 3-4 hours after administration and its 
half-life in plasma is 8-13 hours. 25-30% is excreted by 
renal metabolism (12). 
The most frequent adverse effects are anaemia, haemo-
rrhage and nausea. Like rivaroxaban it is not required a 
routine monitoring. Anyhow, in an emergency situation, 
a calibrated anti-Xa assay is the most sensitive test and 
in major haemorrhages it may be necessary the adminis-
tration of prothrombin complex concentrates (12). 
-Edoxaban
Edoxaxaban, such as Apixaban and Rivaroxaban, is also 
a direct inhibitor of activated factor X (12). The plasma 
concentration peak of edoxaban is 1.5 hours after admi-
nistration and its half-life in plasma it is 10-14 hours. It 
is 35% excreted renally and 60% in faeces (12). 
The most frequent adverse effects are haemorrhage, rash 
and dizziness. As rivaroxaban and apixaban this drug 
does not require a routine monitoring. However, in an 
emergency situation a calibrated anti-Xa assay may be 
useful and in case of severe haemorrhages, it may be 
necessary the administration of prothrombin complex 
concentrates (12).
These new anticoagulants have been progressively pres-
cribed in the treatments of patients who go to the dental 
office without clear indications, warnings, recommenda-
tions or protocols that allow the dentists to perform their 
procedures with the greatest professionalism. Dentists 
are familiarized with traditional anticoagulants (vita-
min K inhibitors) and the methods of monitoring tests 
such as International normalized ratio (INR) and thus 
determine the safety, whether to perform or not an in-
vasive dental treatment that involves bleeding (13-31). 
However, there are not enough reliable clinical trials 
and consensus about the protocol to apply in patients 
on DOACs undergoing dental treatment. Issues such as 
previous discontinuation of the DOAC, the possibility of 
bridging with heparin, prothrombotic risk, and possibili-
ties of bleeding appear more frequently among dentistry 
professionals.
Therefore, it is necessary to address all these issues and 
to summarize them through a review of the literature 
available for the optimal management of these patients 




A comprehensive search of the PubMed, Scopus data-
bases and ISI Web of Science databases from its incep-
tion through October 2016 was conducted to identify 
studies that evaluated the relationship between direct 
oral anticoagulants and dental procedures. We queried 
MeSH terms and the article text for the following search 
terms: (‘dentistry’) OR (‘oral surgery’) AND (‘DOAC’, 
‘NOAC’, ‘TSOAC’, ‘dabigatran’, ‘apixaban’, ‘rivaroxa-
ban’, ‘edoxaban’). The selection criteria were all kind of 
articles (randomized clinical trials, cohort studies, case-
control studies, case series and case reports), performed 
in adult patients under treatment with any kind of DOAC 
drug who underwent a dental procedure that implied any 
kind of bleeding. The search strategy was limited to arti-
cles published in English and human studies.
The articles returned by this search were manually scree-
ned, first on the basis of the title, then the abstract and fi-
nally the complete manuscript, to assess their appropriate-
ness for inclusion in the literature review. References cited 
in these articles were also reviewed to identify additional 
published articles not identified by the database search.
-Data extraction
Two investigators (MZ and NL) independently extracted 
data. The data extracted included information about the 
study design characteristics, the outcomes assessed, the 
cohort characteristics, and the reported results. Disagre-
ements were resolved through consensus.
The quality of the reported information included in each 
article was assessed following the PRISMA statement 
(32) for the improvement of the publication of reviews. 
Results
The process of selection of studies for inclusion in the 
review is summarised in figure 1 (diagram flow). The 
database search identified 30 unique citations, of which 
28 were judged to be of potential interest on the basis 
of the title. On the basis of the abstract, 12 studies were 
reviewed in their entirety.  One study was excluded be-
cause it did not specify the bleeding complications after 
dental treatments. Five additional studies were identified 
after review of the references.
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Fig. 1: Diagram flow of the selection process of the studies included.
Finally, 11 studies that met the criteria described above 
were included in the review (see Tables 2-4).
 
Discussion
There is no consensus in behalf of the protocol to follow 
in patients in treatment with DOACs who need a dental 
procedure or oral surgery. However, all the authors agree 
that it is necessary to individualize each case evaluating 
the difficulty of the procedure, the risk of bleeding, the 
risk of embolism and the renal function of the patient. 
First of all, the articles that focus on the bleeding risk in 
patients treated with dabigatran have similar results and 
conclusions: oral procedures are safe and it is recom-
mended to stop the medication between 12 and 48 hours 
before the procedure. 
The first one, the randomized clinical trial published by 
Healey et al. (10) in 2012, compared the bleeding risk 
in patients treated with dabigatran and warfarin from 
the RE-LY trial. The 25% (n=4591) of patients in each 
group underwent surgery over a 2-year period and 10% 
of these underwent dental procedures. The drugs were 
discontinued prior to surgery, with the last dose of dabi-
gatran given 35–85 h (mean 49 h) prior to the procedure, 
compared to 87–144 h (mean 114 h) for warfarin. There 
was no difference in peri-procedural bleeding between 
the two groups. The authors concluded that are similar 
rates of post-surgery bleeding events and thrombotic 
complications in patients in both groups. The authors 
recommended that for standard bleeding risk procedu-
res, dabigatran should be stopped 2–3 half-lives before 
the procedure, and for high bleeding risk procedures, 
dabigatran should be stopped 4–5 half-lives prior to the 
procedure. 
The case control published by Romond et al. (33) in 
2013, goes in the same direction. The subject of study is 
a male patient of 67 year-old treated with 150mg dabi-
gatran twice a day resumed 1 day after the surgery. After 
8 surgical dental extractions the patient experienced mi-
nimal bleeding reported at the first week follow up. The 
author’s conclusions suggest that in dental extractions 
under dabigatran there is no greater risk of bleeding but 
there should be a consensus between the dentist and the 
physician responsible for the patient regarding the ma-
nagement of the anticoagulant treatment. 
In 2015, Breik et al. (5) published a case series of 5 
patients undergoing simple or multiple dental extrac-
tions treated with dabigatran 220mg/day. The proposed 
author’s protocol in general dental procedures like sin-
J Clin Exp Dent. 2017;9(11):e1346-54.                                                                                                                                                               DOACs in dentistry. Review of literature
e1350
Name Type of study N Dental treatment DOAC Results




459 Dental procedures Dabigatran  2.3% bleeding  (1.9% 
dabigatran 110mg; 3.2% 




Case Report 8 Dental extractions, 
alveoloplasty and 
tuberosity reduction 












No evidence of increased 
bleeding 
More bleeding in heparin 
bridging 
Breik et al. 2014 
(5)
Case series 7 Simple or multiple 
dental extractions 
Dabigatran  n= 1 (14.28%) minor 
postoperative bleeding 
n=1 (14.28%) severe 
postoperative bleeding 




1435 Dental extractions/oral 
surgery 
Apixaban No evidence of increased 
bleeding 
Perioperative bridging is not 
necessary 
Gómez Moreno et
al. 2015 (35) 
Retrospective 
Study 






52 Dental extractions and 
dental implants 




Case series 25 Dental extractions, 




n= 10/25 (40%) clinical 
insignificant bleeding 
Gómez Moreno et
al.  2016 (34) 
Retrospective 
study 


















73 Dental extractions Dabigatran 
Rivaroxaban 
Apixaban 
n= 7 (9.6%) minimal 
bleeding  
Table 2: Studies included in the literature review.
N= expressed as dental procedures.
gle dental extractions, periodontal treatment or root ca-
nal treatment is not to stop dabigatran. The authors also 
recommended after a dental extraction to take haemos-
tatic measures such as mechanical pressure, suture and 
local haemostatic. In multiple extraction procedures, 
it is recommended a consensus with the physician res-
ponsible for the patient and stop dabigatran 24-48 hours 
before the procedure and recommence 24-48 hours post-
procedure. 
The last study of dabigatran was published in 2016 by 
Gomez Moreno et al. (34). This article is about dental 
implant placement in patients taking dabigatran 150mg 
twice a day. They found no statistically significant diffe-
rence in the bleeding events between the dabigatran and 
the control group. They concluded that dental implant sur-
gery can be safely performed in which the last dosage of 
dabigatran was taken at least 12 hours before the procedu-
re, always applying local haemostatic measures (34).
Although the studies have very different characteristics, 
the dental procedures performed are varied and even the 
doses vary, dabigatran seems to be a safe drug that does 
not produce major haemorrhagic complications whether 
it is maintained or withdrawn the last dose. It may also 
be noted that in the case of complex procedures it would 
seem advisable to establish an anticoagulant treatment 
plan agreed with the patient’s reference physician
If we look at articles that evaluate the effects of rivaroxa-
ban, there are some differences regarding the postopera-
tive bleeding risk between the articles reviewed. While 
Gómez Moreno et al. (35) and Abayon et al. (2) found 
that there was no difference in postoperative bleeding, 
Hanken et al. (7) concluded that rivaroxaban has a hig-
her risk of bleeding than other oral anticoagulants. 
The retrospective study conducted in 2015 by Gómez 
Moreno et al. (35) evaluated dental implant surgeries in 
patients taking rivaroxaban without any modification or 
withdrawal of the drug. The postoperative measures per-
formed were non absorbable suture and pressure with 
a gauze impregnated in 5% tranexamic acid during 30-
60 minutes. There was no statistically significant diffe-
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Dental procedures that are unlikely to 
cause bleeding 
Dental procedures that are likely to cause bleeding 
Low risk of post-operative 
bleeding complications 
Higher risk of postoperative bleeding 
complications 
Local anaesthesia by infiltration, 
intreligamentary, mental nerve block 
or inferior dental block.  
Basic periodontal examination.  
Supragingival removal of plaque, 
calculus and stain.  
Direct or indirect restorations with 
supragingival margins.  
Endodontic treatment  
Impressions and other prosthetics 
procedures.  
Fitting and adjustment of orthodontic 
appliances 
Simple extractions (1-3 
teeth, with restricted 
wound size).  
Incision and drainage of 
intraoral swellings 




subgingival scaling.  
Direct or indirect 
restorations with 
subgingival margins
Complex extractions, adjacent extractions 
that will cause a large wound or more than 3 
extractions at once.  
Flap raising procedures:  





Dental implant surgery 
Gingival recontouring  
Biopsies
Table 3: Post-operative bleeding risks for dental procedures (41).
Medical conditions Drug groups
Chronic renal failure 
Liver disease 
Haematological malignancy or myelodysplastic 
disorder
Recent or current chemotherapy 
Advanced heart failure 
Mild forms of inherited bleeding disorders including 
all types of haemophilia and Von Willebrand’s disease 
Idiopathic thrombocytopenic purpura (ITP) 
Combined anticoagulant or antiplatelet drugs  
Cytotoxic drugs or drugs associated with bone 
marrow suppression 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) 
Drugs affecting the nervous system like 
selective serotonin reuptake inhibitors or 
carbamazepine  
Table 4: Medical conditions and drugs associated with increased bleeding risk (41).
rence between the rivaroxaban and the control group in 
the postoperative bleeding. They concluded that dental 
implant surgery in patients taking rivaroxaban is safe, 
with no need to interrupt or modify the medication and 
emphasize the importance to perform postoperative lo-
cal hemostatic measures. Moreover, they highlight that 
dental implant placement has less risk than a dental ex-
traction.
In the same line of conclusions is the case series of 9 
patients published by Abayon et al. (2) in 2016. The sub-
jects evaluated were in treatment with rivaroxaban 20mg 
hours that continued, partial interrupt or complete inte-
rrupt the anticoagulant treatment. They conducted all 
types of dental treatment (dental extractions, dental pro-
phylaxis, dental restorations or periodontal treatment). 
They concluded that dental treatment may be safely per-
formed following the three strategies, but they pointed 
out that larger scale comparative studies are necessary 
to assess the preferred approach.
On the other hand, we have the retrospective study pu-
blished by Hanken et al. (7) in 2015. This study evaluated 
337 oral procedures (327 dental extractions and 10 den-
tal implants) in patients in treatment with Rivaroxaban 
20mg/day without stopping the medication comparing 
with healthy subjects. They concluded that Rivaroxaban 
increases postoperative bleeding risk to 11.5%, which 
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is a higher level compared to other oral anticoagulants. 
However, all the bleeding events were manageable with 
local compression, fibrin glue and secondary suture.
In the case of rivaroxaban the conclusions regarding 
bleeding rate are not homogeneous since there is at least 
one study in which it has been evidenced that the pa-
tients have a greater tendency to haemorrhage although 
the management is affordable.
There are two studies that evaluate the bleeding risk of 
apixaban. First, Garcia et al. (36) compared the bleeding 
risk in patients treated with apixaban and warfarin from 
the ARISTOTELE trial. Garcia et al. (36) used data from 
this trial to identify all patients who ‘‘underwent a pro-
cedure for which anticoagulant therapy would, in some 
clinical situations, be interrupted’’. Dental extraction/
oral surgery accounted for 14.6% of all procedures. The 
authors concluded that the risk of or major bleeding in 
the procedures was low and similar rates of major blee-
ding events and thromboembolism took place in both 
groups during the 30 days after procedures. Abayon et 
al. (2) performed a study which includes a group of pa-
tients with different types of dental interventions as we 
have noted above, in which three different strategies are 
established: regarding anticoagulation continued, partial 
interrupt or complete interrupt, and there are not diffe-
rences in bleeding.
Despite the limited data available, we can extract that 
apixaban is at least as safe as warfarin in terms of blee-
ding and the appearance of new cardiovascular events; 
and that remove or maintain the drug in dental procedu-
res does not imply a higher rate of haemorrhagic com-
plications. 
Finally, of the reviewed, there are other articles that 
compare different types of oral anticoagulants, like war-
farin and all kind of DOACs and also take into account 
anticoagulant withdrawal bridged with heparin. 
In 2013, Beyer-Westendorf et al. (37) analysed data from 
a prospective registry of over 2100 patients to study the 
peri-procedural management of DOACs. The patients 
in the study were taking rivaroxaban (76%), dabigatran 
(23.5%) and apixaban (0.5%). Procedures were catego-
rized into minimal procedures (including nonextraction 
dental procedures) and minor procedures (including 
dental extractions).  The authors analysed the role of he-
parin bridging in this type of patients and concluded that 
the prevalence of bleeding was found to be higher in the 
groups of patients who had received heparin bridging, as 
might be expected, without affecting the risk of a throm-
boembolic event. They concluded that heparin bridging 
was therefore not recommended in the peri-procedural 
management of patients taking DOACs, and short-term 
interruption appeared to be safe in the minimal and mi-
nor surgery groups. In the same line Garcia et al. (36) 
concluded that heparin bridging was not recommended 
in the peri-procedural management of patients taking 
apixaban and Clemm et al. (38) that the heparin bridging 
may be associated with a higher postoperative bleeding 
risk.
In 2016, Clemm et al. (38) conducted a prospective 
comparative study to analyse the postoperative bleeding 
risk in of patients undergoing dental implant and bone 
graft surgeries without stopping their anticoagulation 
treatment. They compared patients treated with i) pla-
telet aggregation inhibitors, ii) vitamin K inhibitors, iii) 
vitamin K inhibitor withdrawal bridged with heparin and 
iv) direct oral anticoagulants. The percentage of patients 
that experienced postoperative bleeding was 1.2%. None 
of the patients with DOACs presented bleeding, and the 
group with more frequency of bleeding was the vitamin 
K withdrawal bridged with heparin. They concluded that 
the bleeding risk after implant surgery and bone grafting 
procedures is very low in patients continuing the anti-
coagulation treatment, that DOACs do not significantly 
increase this risk.
Also in 2016 Mauprivez et al. (39) conducted a pros-
pective observational study to compare the incidence of 
postoperative bleeding after dental extractions between 
patients treated with DOACs and patients treated with 
Vitamin K antagonists without withdrawal of the anti-
coagulant treatment. The bleeding events that took place 
were mild and easily controlled and were comparable 
between the two groups. They concluded that dental ex-
tractions can be safely performed in patients treated with 
DOACs without interrupting or modifying the dose. 
Although the patient groups and their medications are 
very heterogeneous, these findings are in agreement 
with the previously mentioned study and we can con-
clude that the new anticoagulants compared with the 
vitamin K antagonists do not seem to produce greater 
haemorrhagic complications.
We can also extract from various studies (Garcia et al. 
(36) Beyer-Westendorf et al. (37) and Clemm et al. 
(38) that heparin bridging was not recommended in the 
peri-procedural management of patients taking DOACs 
because may be associated with a higher postoperative 
bleeding risk.
The latest quality non-systematic reviews published by 
Elad (12) and Johnston (40) in 2016 have similar con-
clusions to our review and agree that there is lack of 
scientific evidence in order to establish a protocol for 
dental procedures in patients treated with DOACs and 
that more comparative clinical trials are needed. In both 
reviews is pointed out that, before the dental procedure, 
it is important to assess the type of procedure, the extent 
of expected bleeding and the medical background of the 
patient. Moreover, whether to discontinue or not the an-
ticoagulant treatment, there is consensus that the prefe-
rred approach is to continue the drug or time the dental 
treatment as late as possible after the las DOACs dose; 
since local haemostatic measures are likely to be suffi-
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cient and the risk of a thromboembolic event if DOACs 
are stopped is higher than the bleeding risk after a dental 
procedure.
All these recommendations are in the same line with 
the guideline of the NHS and the Scottish Dental Cli-
nical Effectiveness Program on the Management of 
Dental Patients Taking Anticoagulants or Antiplatelet 
Drugs, summarized by Daly (41). This paper suggests 
two different approaches depending on the type of den-
tal procedure and the risk of bleeding based on certain 
clinical characteristics of patients which are summarized 
in tables 3 and 4. In dental procedures with low risk of 
bleeding complications it is not necessary to interrupt 
the anticoagulant medications. However, in dental pro-
cedures with higher risk of bleeding complications, it is 
recommended to advise the patient to miss or delay their 
morning dose on the day of the dental treatment. The 
patients can restart their medication only when haemos-
tasis has been achieved.
Based on the studies analysed we can support the fo-
llowing conclusions regarding the use of DOACs in den-
tal practice,
DOACs are relatively safe drugs in terms of bleeding. 
They can be compared with classic oral anticoagulants. 
Removal of the anticoagulant a few hours before the 
procedure appears to be an adequate approach that does 
not increase the risk of thromboembolic events. Howe-
ver when dental procedures are performed without wi-
thdrawal of the drug the bleeding is manageable with 
conventional haemostasis measurements. The bridging 
approach with heparin does not seem to be recommen-
ded in any case because precisely these changes in an-
ticoagulant treatment appear to increase post-operative 
bleeding.
In complex patients, with clinical characteristics pre-
disposing to bleeding and even in complex and invasi-
ve dental procedures it is necessary an individualized 
approach with the consensus between the dentist and 
the patient´s responsible physician in order to minimize 
risks and possible complications.
The available scientific evidence regarding the mana-
gement of these drugs in the dental office is very weak 
and therefore will be necessary to carry out solid clinical 
trials to confirm these initial conclusions.  
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